XYD224: In Vivo Antitumor Activity of a BRD9 Degrader for Acute Myeloid Leukemia

A 2.3 KB dataset from figshare, authored by Xin Tang and last updated in May 2026, describes the preclinical evaluation of a BRD9-targeting PROTAC compound. The data likely contains results from in vitro cell line assays and in vivo xenograft models, including IC50 and tumor growth inhibition rates. The findings support the compound's advancement as a therapeutic candidate for acute myeloid leukemia.

Use Cases

• Modeling dose-response relationships based on IC50 values mentioned for AML cell lines
• Analyzing in vivo efficacy based on tumor growth inhibition rates from the MV4-11 xenograft model
• Studying degradation mechanisms based on described time-, dose-, CRBN-, and proteasome-dependency
• Comparing compound potency across different AML cell lines referenced in the description

Strengths

• Includes specific quantitative results, such as an IC50 of 33 nM in MV4-11 cells and tumor growth inhibition rates of 70% and 79% at specified doses.
• The description provides a clear mechanistic context for the data, detailing the compound's dependency on CRBN and the proteasome.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 2.3 KB, indicating a limited scope of data.

Provenance

Source

figshare

Collection Method

Likely contains synthesized experimental results from drug discovery research.

Freshness

Last updated 2026-05-28 05:15:48; freshness should be verified.